Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis sees Alcon helping to drive group growth as reimbursements falls 10%

This article was originally published in Scrip

Executive Summary

Novartis has issued an update on the growth prospects of the group, and of the Alcon eye care business it acquired for around $52 billion in staggered transactions completed in April. It expects new product launches, along with its business in fast-growing emerging markets, to offset significant patent expiries (for Femara, Diovan and Zometa) over the next couple of years and drive sales growth, with improved productivity, efficiency savings, economies of scale and better procurement enabling operating income to grow faster than sales.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts